Fremont, California, March 17, 2026
Alamar Biosciences, Inc. announced the launch of its NULISAseq™ Neuro 220 Panel, a next-generation precision proteomics platform designed to advance research in neurodegenerative diseases through ultra-high sensitivity and multiplex biomarker detection. The panel enables simultaneous measurement of 220 protein biomarkers from a single sample, significantly expanding the scope of neurological research and providing a powerful tool for early disease detection, biomarker discovery, and translational research.
Advanced Proteomics Platform Expands Neurological Biomarker Coverage
The NULISAseq Neuro 220 Panel builds upon Alamar’s existing CNS disease panel by introducing expanded biomarker coverage for Alzheimer’s and Parkinson’s diseases, including 15 newly developed biomarkers supported by The Michael J. Fox Foundation. A key innovation of the platform is its comprehensive suite of Tau protein assays, which includes both brain-derived and peripheral isoforms as well as multiple phosphorylated variants such as pTau217, pTau181, pTau205, pTau212, and pTau231.
This represents one of the most extensive Tau biomarker panels available, enabling researchers to differentiate organ-specific isoforms and post-translational modifications with high precision. The platform’s ability to capture complex molecular signatures supports deeper insights into disease progression, pathology, and heterogeneity, addressing critical challenges in neurodegenerative disease research.
Enabling Early Detection and Precision Medicine in Neurology
Advertisement
The panel is designed to support early and pre-symptomatic detection of neurological disorders, leveraging ultra-high sensitivity and specificity to detect low-abundance biomarkers in minimally invasive samples. This capability is particularly important for diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis, where early diagnosis remains a major unmet need. The platform is also compatible with automated workflows using the ARGO™ HT System, ensuring high reproducibility, scalability, and ease of use in both research and clinical settings.
By enabling large-scale, high-resolution analysis of protein biomarkers, the NULISA platform facilitates the identification of prognostic indicators, therapeutic response markers, and co-pathologies, accelerating the transition from basic research to clinical applications and precision medicine strategies.
Accelerating Translational Research Through Scientific Collaboration
Alamar’s innovation is further strengthened through collaboration with leading research organizations, including The Michael J. Fox Foundation, which contributed to the development of Parkinson’s disease biomarkers. The platform will be prominently featured at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2026) in Copenhagen, where data will be presented across multiple scientific sessions and posters, demonstrating its utility in advancing neurological research.
Experts highlight that the ability to measure a broad array of biomarkers in a single assay represents a significant advancement in both translational and clinical research, enabling more comprehensive understanding of disease mechanisms. By integrating cutting-edge proteomics technology with collaborative research efforts, Alamar is helping to drive innovation in diagnostic development, therapeutic discovery, and personalized medicine.
Source: Alamar Biosciences press release
